3 unchanged sentences
By-Laws of the Company, as amended through June 29, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K dated June 30, 2020 and incorporated herein by reference).
+Added: Fourteenth Amendment to lease dated July 17, 1990, made as of November 11, 2021 by and between Buncher Company and the Company for property located in Leetsdale, Pennsylvania (1).
+Added: CFO Retention and Transition Agreement, dated as of November 8, 2021, by and between the Company and William P.
Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Christopher A.
4 unchanged sentences
Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of William Burke, Executive Vice President, Chief Financial Officer of the Company.
−Removed: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended October 2, 2021, formatted in inline Extensible Business Reporting Language (XBRL) includes:
+Added: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended January 1, 2022 formatted in inline Extensible Business Reporting Language (XBRL) includes:
(i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.
104* Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
−Removed: * In accordance with Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, is deemed not filed for the purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.
+Added: * Document filed with this report.
+Added: ** Document furnished with this report.
+Added: (1) Certain portions of this exhibit are considered confidential and have been omitted as permitted under SEC rules and regulations.
+Added: (2) Agreement, plan or arrangement related to the compensation of officers or directors.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HAEMONETICS CORPORATION
−Removed: November 9, 2021 By:
+Added: February 8, 2022 By:
/s/ Christopher A.
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 9, 2021 By:
+Added: February 8, 2022 By:
/s/ William Burke
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.